EP. 1: European Commission Approval of Tucatinib in HER2+ BC
Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.
EP. 2: Favorable Safety Profile of Tucatinib for Metastatic HER2+ BC
Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.
EP. 3: Real-World Experience With Tucatinib in Germany and France
An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.
EP. 4: Clinical Implications of Tucatinib Approval in Europe
Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.
EP. 5: Approaches to Sequencing for Metastatic HER2+ BC
Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.
EP. 6: Unanswered Questions in HER2+ Breast Cancer
Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.